IDENTIFICATION OF URINARY MICROBIOTE IN PATIENTS WITH DIAGNOSTIC-RELATED CYSTOSCOPY

IDENTIFICATION OF URINARY MICROBIOTE IN PATIENTS WITH DIAGNOSTIC-RELATED CYSTOSCOPY

Sponsors

Lead Sponsor: Assistance Publique Hopitaux De Marseille

Source Assistance Publique Hopitaux De Marseille
Brief Summary

Identify by culture the urinary microbiota of patients with bladder cancer (at the time of diagnosis) and controls.Identify by metagenomics the urinary microbiota of patients with bladder cancer (at the time of diagnosis) and controls.

Detailed Description

Relationships between the human microbiota and various pathologies such as cancer have been demonstrated. The microbiota would have an influence on the effectiveness of anticancer treatments.

Bladder cancers are five times more common in men than women, and this difference in incidence has long been explained by a higher smoking rate among men. However, the increase in smoking among women has not led, as in the case of lung cancer, to a significant increase in bladder cancer among them.

Urine bladder has long been considered "sterile" by generations of researchers. Recent studies have shown that most urine is not sterile but instead contains a different microbiota in both men and women. In women Actinobacteria, including Mycobacteria, and Bacteroidetes have been detected.

BCG therapy is used in the treatment of bladder cancer. BCG, in addition to being a vaccine to prevent tuberculosis, is a mycobacterium belonging to the phylum Actinobacteria [4]. Controversial studies have suggested the same potential for Lactobacillus casei. Lactobacillii are Firmicutes found both in the urinary microbiota of men and women.

Thus microbiota composed mainly of Actinobacteria could be associated with a lower incidence of bladder cancers in women.

Overall Status Not yet recruiting
Start Date September 1, 2019
Completion Date September 30, 2021
Primary Completion Date March 30, 2020
Study Type Observational [Patient Registry]
Primary Outcome
Measure Time Frame
Matrix Assisted Laser Desorption Ionisation - Time of Flight 1 day
Enrollment 100
Condition
Eligibility

Sampling Method: Probability Sample

Criteria:

Inclusion Criteria:

- Person receiving a cystoscopy in the context of a suspicion of bladder cancer

- Person and / or legal guardian for minors who have been informed about the study and have not expressed opposition to participate in the study.

- Affiliated person or beneficiary of a social security scheme.

Exclusion Criteria:

- Vulnerable person: pregnant, parturient or nursing woman,

- person under guardianship or curatorship, or deprived of liberty by a judicial or administrative decision.

- Person treated with antibiotics

Gender: All

Minimum Age: 18 Years

Maximum Age: N/A

Healthy Volunteers: No

Overall Contact

Last Name: Didier Raoult

Phone: 04 13 73 24 01

Email: [email protected]

Verification Date

July 2019

Responsible Party

Type: Sponsor

Has Expanded Access No
Arm Group

Label: Patients with cancer

Description: 50 patients ultimately diagnosed with bladder cancer and 50 control patients (diagnosis of cancer reversed at cystoscopy or cystoscopy for another cause)

Study Design Info

Observational Model: Other

Time Perspective: Other

Source: ClinicalTrials.gov